Westpac Banking Corp Has $11.68 Million Holdings in Bristol Myers Squibb Company $BMY

Westpac Banking Corp lessened its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 4.5% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 192,545 shares of the biopharmaceutical company’s stock after selling 9,170 shares during the period. Bristol Myers Squibb makes up approximately 0.8% of Westpac Banking Corp’s investment portfolio, making the stock its 18th largest position. Westpac Banking Corp’s holdings in Bristol Myers Squibb were worth $11,678,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in BMY. Brighton Jones LLC boosted its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the period. Sivia Capital Partners LLC increased its position in Bristol Myers Squibb by 59.4% during the 2nd quarter. Sivia Capital Partners LLC now owns 7,477 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 2,786 shares during the period. United Bank lifted its holdings in shares of Bristol Myers Squibb by 15.0% during the second quarter. United Bank now owns 25,148 shares of the biopharmaceutical company’s stock worth $1,164,000 after buying an additional 3,277 shares in the last quarter. Marshall Wace LLP bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $221,000. Finally, Nebula Research & Development LLC bought a new stake in shares of Bristol Myers Squibb in the second quarter valued at about $405,000. Institutional investors own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA collaboration and plans to deploy a next-generation DGX SuperPOD AI system to speed drug discovery, a potentially positive long-term productivity and innovation catalyst. Article Title
• Positive Sentiment: The company said it will be the first life sciences firm to buy NVIDIA’s DGX SuperPOD based on Vera Rubin systems, highlighting an aggressive push into advanced AI infrastructure for drug development. Article Title
• Positive Sentiment: Bristol Myers is also being viewed as a peer in next-generation cancer treatment innovation, with its bispecific antibody work alongside BioNTech mentioned in coverage of therapies that could help replace older blockbuster drugs over time. Article Title
• Neutral Sentiment: Healthcare stocks traded lower late Monday afternoon, which could have offset some of the positive company-specific momentum in BMY. Article Title

Bristol Myers Squibb Stock Up 1.2%

NYSE BMY opened at $60.89 on Wednesday. The business has a fifty day moving average price of $57.20 and a two-hundred day moving average price of $57.90. The stock has a market capitalization of $124.34 billion, a PE ratio of 17.10, a PEG ratio of 0.17 and a beta of 0.23. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the company posted $1.80 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Wall Street Analyst Weigh In

BMY has been the topic of a number of recent research reports. Bank of America lowered their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating on the stock in a research report on Friday, July 10th. Cantor Fitzgerald reissued a “neutral” rating and issued a $54.00 price objective on shares of Bristol Myers Squibb in a report on Monday, July 6th. UBS Group restated a “buy” rating on shares of Bristol Myers Squibb in a research report on Thursday, May 28th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $61.25.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.